These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 39029987)
1. Therapeutic potential of cannabidiol in depression. Guldager MB; Chaves Filho AM; Biojone C; Joca S Int Rev Neurobiol; 2024; 177():251-293. PubMed ID: 39029987 [TBL] [Abstract][Full Text] [Related]
2. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. Silote GP; Sartim A; Sales A; Eskelund A; Guimarães FS; Wegener G; Joca S J Chem Neuroanat; 2019 Jul; 98():104-116. PubMed ID: 31039391 [TBL] [Abstract][Full Text] [Related]
3. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs. Quesseveur G; Gardier AM; Guiard BP Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973 [TBL] [Abstract][Full Text] [Related]
4. Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: Modulation of inflammatory pathways. Florensa-Zanuy E; Garro-Martínez E; Adell A; Castro E; Díaz Á; Pazos Á; Mac-Dowell KS; Martín-Hernández D; Pilar-Cuéllar F Biochem Pharmacol; 2021 Mar; 185():114433. PubMed ID: 33513342 [TBL] [Abstract][Full Text] [Related]
5. Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain. Tito PAL; Bernardino TCS; Bellozi PMQ; da Silva MCM; de Miranda AS; Vieira ÉLM; Moreira FA; Palotás A; de Oliveira ACP; Reis HJ Pharmacol Rep; 2021 Dec; 73(6):1680-1693. PubMed ID: 34218397 [TBL] [Abstract][Full Text] [Related]
6. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Bymaster FP; McNamara RK; Tran PV Expert Opin Investig Drugs; 2003 Apr; 12(4):531-43. PubMed ID: 12665410 [TBL] [Abstract][Full Text] [Related]
7. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. Niciu MJ; Ionescu DF; Richards EM; Zarate CA J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540 [TBL] [Abstract][Full Text] [Related]
8. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Hillhouse TM; Porter JH Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025 [TBL] [Abstract][Full Text] [Related]
9. Repeated cannabidiol treatment affects neuroplasticity and endocannabinoid signaling in the prefrontal cortex of the Flinders Sensitive Line (FSL) rat model of depression. Domingos LB; Müller HK; da Silva NR; Filiou MD; Nielsen AL; Guimarães FS; Wegener G; Joca S Neuropharmacology; 2024 May; 248():109870. PubMed ID: 38401791 [TBL] [Abstract][Full Text] [Related]
11. Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus. Abame MA; He Y; Wu S; Xie Z; Zhang J; Gong X; Wu C; Shen J Neurosci Lett; 2021 Jan; 744():135594. PubMed ID: 33388355 [TBL] [Abstract][Full Text] [Related]
12. The contribution of proteomic studies in humans, animal models, and after antidepressant treatments to investigate the molecular neurobiology of major depression. Carboni L Proteomics Clin Appl; 2015 Oct; 9(9-10):889-98. PubMed ID: 25488430 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505 [TBL] [Abstract][Full Text] [Related]
14. Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Tartt AN; Mariani MB; Hen R; Mann JJ; Boldrini M Mol Psychiatry; 2022 Jun; 27(6):2689-2699. PubMed ID: 35354926 [TBL] [Abstract][Full Text] [Related]
15. Preclinical discovery of duloxetine for the treatment of depression. Torres-Sanchez S; Perez-Caballero L; Mico JA; Elorza J; Berrocoso E Expert Opin Drug Discov; 2012 Aug; 7(8):745-55. PubMed ID: 22680253 [TBL] [Abstract][Full Text] [Related]
16. Targeting inflammatory pathways for treatment of the major depressive disorder. Patil CR; Suryakant Gawli C; Bhatt S Drug Discov Today; 2023 Sep; 28(9):103697. PubMed ID: 37422168 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders. Yousaf M; Chang D; Liu Y; Liu T; Zhou X Molecules; 2022 Aug; 27(15):. PubMed ID: 35956911 [TBL] [Abstract][Full Text] [Related]
18. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. Pitsillou E; Bresnehan SM; Kagarakis EA; Wijoyo SJ; Liang J; Hung A; Karagiannis TC Mol Biol Rep; 2020 Jan; 47(1):753-770. PubMed ID: 31612411 [TBL] [Abstract][Full Text] [Related]
19. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331 [TBL] [Abstract][Full Text] [Related]
20. Promising new pharmacological targets for depression: The search for efficacy. Tsugiyama LE; Macedo Moraes RC; Cavalcante Moraes YA; Francis-Oliveira J Drug Discov Today; 2023 Dec; 28(12):103804. PubMed ID: 37865307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]